User: Guest  Login
Title:

From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.

Document type:
Journal Article
Author(s):
Aly, Lilian; Hemmer, Bernhard; Korn, Thomas
Abstract:
Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents have been approved or are filed for licensing as MS therapeutics. Due to semi-selective targeting of cellular processes, these second-generation immunosuppressive compounds might rather be immunomodulatory. For example, Teriflunomide inhibits the de novo pyrimidine synthesis and thus only targets rapidly proliferating cells, includ...     »
Journal title abbreviation:
Curr Neuropharmacol
Year:
2017
Journal volume:
15
Journal issue:
6
Pages contribution:
874-891
Language:
eng
Fulltext / DOI:
doi:10.2174/1570159X14666161208151525
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/27928949
Print-ISSN:
1570-159X
TUM Institution:
Molekulare Immunologie (Prof. Knolle); Neurologische Klinik und Poliklinik
 BibTeX